Win for Pfizer and Flynn in UK price gouging case

8 June 2018

Drugmakers Pfizer (NYSE: PFE) and Flynn Pharma have successfully overturned fines of nearly nearly £90 million ($120 million) levied by the UK’s competition authority in 2016 over allegations of price gouging.

The Competition Appeal Tribunal says the Competition and Markets Authority (CMA) had failed to demonstrate that the ramping up of the cost of an epilepsy drug was in breach of competition law.

Pfizer manufactures phenytoin sodium capsules and supplies them to Flynn Pharma, which distributes them to UK wholesalers and pharmacies. The CMA’s allegations relate to both the prices Pfizer charged to Flynn Pharma and that Flynn Pharma charged to its customers, since September 2012.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK